Incyte is a biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The Company develops Jakafi (ruxolitinib), a drug for the treatment of intermediate or high-risk myelofibrosis, a type of myeloproliferative disorder that affects the bone marrow, and for polycythemia vera when there has been an inadequate response to or intolerance of hydroxyurea.